CliffBio
small molecule

LUMISIGHT

PEGULICIANINE ACETATE

Loss of exclusivitySeptember 2034latest FDA-listed patent expiry
CompanyLumicell →See this company's full patent-cliff portfolio

Drug detail

Brand nameLUMISIGHT
Active ingredientPEGULICIANINE ACETATE
StrengthEQ 39MG BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2024
Marketing statusRX

Listed patents

PatentExpiresType
9763577September 2034substance, product
10285759December 2031use U-3890
9532835December 2031use U-3890
9032965December 2031use U-3890
9155471October 2031use U-3890
11592396September 2030substance

Regulatory exclusivity

CodeExpires
NCEApril 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.